^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CXCL13 expression

    i
    Other names: CXCL13, ANGIE, ANGIE2, BCA-1, BLC, BLR1L, SCYB13, Chemokine (C-X-C motif) ligand 13
    Entrez ID:
    10563
    Related biomarkers:
    Expression
    Mutation
    Others
    11ms
    Acquisition of discrete immune suppressive barriers contributes to the initiation and progression of preinvasive to invasive human lung cancer. (PubMed, bioRxiv)
    The single-cell architecture identifies determinants of early disease emergence and progression, which may be developed not only as diagnostic/prognostic biomarkers but also as targets for disease interception. Additionally, our dataset constitutes a valuable resource for the preinvasive lung cancer research community.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • TREM2 (Triggering Receptor Expressed On Myeloid Cells 2)
    |
    CD8 expression • CXCL13 expression
    11ms
    Sex-related differences in the morphology of rectal mucosa-associated lymphoid tissues in C57BL/6NCrSlc mice. (PubMed, Histol Histopathol)
    The factors influencing RMALT development, such as the presence of HEVs, C-X-C motif chemokine ligand 13 expression, and RMALT-containing cell proliferation, were also explored. Overall, this study revealed the detailed attributes of RMALTs, their immune cell composition, and their determinants in male and female mice, providing insights into the sex-specific characteristics of the rectal mucosal immune system.
    Preclinical • Journal
    |
    CXCL13 (Chemokine (C-X-C motif) ligand 13)
    |
    CXCL13 expression • CXCL8 expression
    1year
    Skin immune-mesenchymal interplay within tertiarylymphoid structures promotes autoimmunepathogenesis in hidradenitis suppurativa. (PubMed, Immunity)
    Using a microfluidic system to mimic TLS on a chip, we found that HS fibroblasts critically orchestrated lymphocyte aggregation via tumor necrosis factor alpha (TNF-α)-CXCL13 and TNF-α-CCL19 feedback loops with B and T cells, respectively; early TNF-α blockade suppressed aggregate initiation. Our findings provide insights into TLS formation in the skin, suggest therapeutic avenues for HS, and reveal mechanisms that may apply to other autoimmune settings, including Crohn's disease.
    Journal
    |
    IFNG (Interferon, gamma) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • CCL19 (C-C Motif Chemokine Ligand 19) • IL17A (Interleukin 17A)
    |
    CXCL13 expression
    1year
    Identification and phenotypic characterization of neoantigen-specific cytotoxic CD4+ T cells in endometrial cancer. (PubMed, Cancer Immunol Res)
    The identified neoantigen-specific CD4+ T cells were found exclusively in one of the CXCL13+ subclusters characterized by granzyme B and CCL5 expression. These results demonstrate the involvement of tumor-reactive CD4+ T cells with cytotoxic function in immune surveillance of endometrial cancer and reveal their transcriptomic signature.
    Journal • IO biomarker
    |
    CD4 (CD4 Molecule) • CCL5 (Chemokine (C-C motif) ligand 5) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • GZMB (Granzyme B)
    |
    CXCL13 expression
    1year
    PANoptosis-Relevant Subgroups Predicts Prognosis and Characterizes the Tumour Microenvironment in Ovarian Cancer. (PubMed, J Inflamm Res)
    We initially identified the molecular subtypes associated with PRGs and established a prognostic model related to PRGs to predict survival and drug response in OC patients. Although further validation is required, these findings offer valuable insights into the development of personalized treatment strategies for OC patients.
    Journal • IO biomarker
    |
    CXCL13 (Chemokine (C-X-C motif) ligand 13)
    |
    CXCL13 expression
    1year
    Mapping of the T Cell Landscape of Biliary Tract Cancer Unravels Anatomical Subtype-Specific Heterogeneity. (PubMed, Cancer Res)
    Inhibition of LGALS1 reduced tumor growth and Treg prevalence in ICC mouse models. Overall, this study unveils T cell diversity across BTC subtypes at the single-cell and spatial level that could open paths for tailored immunotherapies.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • LGALS1 (Galectin 1) • CXCL13 (Chemokine (C-X-C motif) ligand 13)
    |
    CD4 expression • CXCL13 expression
    1year
    Tumor-specific antibodies elicited by engineered bacteria promote bladder cancer immunotherapy. (PubMed, bioRxiv)
    Furthermore, when combined with PD-1 blockade, engineered EcN amplified the antitumor antibody response and promoted long-term survival and protective immunity upon tumor rechallenge. Thus, we demonstrate that synthetically engineered CXCL13-expressing EcN can enhance the efficacy of PD-1 checkpoint blockade immunotherapy by amplifying tumor-specific humoral immunity.
    Journal
    |
    CXCL13 (Chemokine (C-X-C motif) ligand 13)
    |
    CXCL13 expression
    1year
    Chemokine Profile Is Different in Normal Testis Compared to Seminoma - Especially in Tumor Infiltrating Lymphocytes. (PubMed, Anticancer Res)
    The involvement of TILs in seminoma biology warrants further investigation, especially their role in the tumor micro-environment and pathogenesis. Chemokine and Ki-67 expression in TILs could serve as potential markers for assessing seminoma prognosis.
    Journal • Tumor-infiltrating lymphocyte
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • CXCR5 (C-X-C Motif Chemokine Receptor 5)
    |
    CXCL13 expression
    1year
    Study on correlation between CXCL13 and prognosis and immune characteristics of ovarian cancer. (PubMed, Medicine (Baltimore))
    Moreover, high expression of CXCL13 was related to a better tumor response and more extended tumor-stable stage after PD-1 blocking therapy in IMvigor210. The study concluded that CXCL13 could be a prognostic marker and a potential immunotherapy target for OC patients, especially PD-1 checkpoint blockade.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CXCL13 (Chemokine (C-X-C motif) ligand 13)
    |
    PD-1 expression • CXCL13 expression
    1year
    A novel strategy of co-expressing CXCR5 and IL-7 enhances CAR-T cell effectiveness in osteosarcoma. (PubMed, Front Immunol)
    Mechanistically, C5/IL7-CAR-T cells displayed enhanced STAT5 signaling. These findings highlight the potential of CXCR5 and IL-7 co-expression to improve CAR-T cell therapy efficacy against osteosarcoma.
    Journal • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • PD-1 (Programmed cell death 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • IL7 (Interleukin 7) • MICA (MHC Class I Polypeptide-Related Sequence A) • STAT5A (Signal Transducer And Activator Of Transcription 5A) • MICB (MHC Class I Polypeptide-Related Sequence B) • NKG2D (killer cell lectin like receptor K1)
    |
    PD-1 expression • BCL2 expression • HAVCR2 expression • CXCL13 expression • CXCR5 expression
    1year
    The A2AR antagonist inupadenant promotes humoral responses in patients (ESMO-IO 2024)
    These effects may play a substantial role in delaying progression in end-stage patients. Additional work is ongoing to demonstrate this new mechanism of action across clinical settings and patient populations.
    Clinical
    |
    CXCL13 (Chemokine (C-X-C motif) ligand 13) • ADORA2A (Adenosine A2a Receptor)
    |
    CXCL13 expression
    |
    nCounter® PanCancer IO 360™ Panel
    |
    inupadenant (EOS-850)
    1year
    Serum CXCL13 as a Novel Biomarker in Oral Squamous Cell Carcinoma. (PubMed, Cancer Med)
    These findings imply that serum CXCL13 holds diagnostic and prognostic value, showing promise as a novel biomarker for OSCC.
    Journal
    |
    CD8 (cluster of differentiation 8) • CXCL13 (Chemokine (C-X-C motif) ligand 13)
    |
    CD8 expression • CXCL13 expression • CXCL13 overexpression